Next Article in Journal
Effectiveness and Efficacy of Vaccine on Mutated SARS-CoV-2 Virus and Post Vaccination Surveillance: A Narrative Review
Previous Article in Journal
What Determines Vaccine Hesitancy: Recommendations from Childhood Vaccine Hesitancy to Address COVID-19 Vaccine Hesitancy
Previous Article in Special Issue
Evaluating the Geographical Accessibility and Equity of COVID-19 Vaccination Sites in England
Project Report

The Burden of COVID-19 in Children and Its Prevention by Vaccination: A Joint Statement of the Israeli Pediatric Association and the Israeli Society for Pediatric Infectious Diseases

1
Infectious Diseases and Infection Control Unit, Hillel Yaffe Medical Center, Hadera 3810101, Israel
2
Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Haifa 3109601, Israel
3
Department of Day Care Hospitalization, Schneider Children’s Medical Center, Petah Tikva 4920235, Israel
4
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo 6997801, Israel
5
The Pediatric Infectious Disease Unit, Soroka Medical Center, Be’er Sheva 8458900, Israel
6
The Faculty of Health Sciences, Joyce & Irving Goldman Medical School at Ben Gurion University of the Negev, Be’er Sheva 8410501, Israel
7
Pediatric Department, E. Wolfson Medical Center, Holon 5822012, Israel
8
Department of Pediatrics A, Schneider Children’s Medical Center, Petah Tikva 4920245, Israel
9
Maccabi Healthcare Services, Tel Aviv-Yafo 6812509, Israel
10
Jerusalem District Health Office, Jerusalem 9137001, Israel
11
Braun School of Public Health and Community Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel
12
Schneider Children’s Medical Center, Petah Tikva 4920235, Israel
13
Adelson School of Medicine, Ariel University, Ari’el 4070000, Israel
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Barbara Rath
Vaccines 2022, 10(1), 81; https://doi.org/10.3390/vaccines10010081
Received: 30 November 2021 / Revised: 23 December 2021 / Accepted: 29 December 2021 / Published: 6 January 2022
(This article belongs to the Special Issue Vaccines: Uptake and Equity in Times of the COVID-19 Pandemic)
As of October 2021, SARS-CoV-2 infections were reported among 512,613 children and adolescents in Israel (~33% of all COVID-19 cases). The 5–11-year age group accounted for about 43% (223,850) of affected children and adolescents. In light of the availability of the Pfizer-BioNTech BNT162b2 vaccine against COVID-19 for children aged 5–11 years, we aimed to write a position paper for pediatricians, policymakers and families regarding the clinical aspects of COVID-19 and the vaccination of children against COVID-19. The first objective of this review was to describe the diverse facets of the burden of COVID-19 in children, including the direct effects of hospitalization during the acute phase of the disease, multisystem inflammatory syndrome in children, long COVID and the indirect effects of social isolation and interruption in education. In addition, we aimed to provide an update regarding the efficacy and safety of childhood mRNA COVID-19 vaccination and to instill confidence in pediatricians regarding the benefits of vaccinating children against COVID-19. We reviewed up-to-date Israeli and international epidemiological data and literature regarding COVID-19 morbidity and its sequelae in children, vaccine efficacy in reducing COVID-19-related morbidity and SARS-CoV-2 transmission and vaccine safety data. We conducted a risk–benefit analysis regarding the vaccination of children and adolescents. We concluded that vaccines are safe and effective and are recommended for all children aged 5 to 11 years to protect them from COVID-19 and its complications and to reduce community transmissions. Based on these data, after weighing the benefits of vaccination versus the harm, the Israeli Ministry of Health decided to recommend vaccination for children aged 5–11 years. View Full-Text
Keywords: COVID-19; children; adolescents; vaccine; risk-benefit; efficacy; safety; transmission COVID-19; children; adolescents; vaccine; risk-benefit; efficacy; safety; transmission
Show Figures

Figure 1

MDPI and ACS Style

Stein, M.; Ashkenazi-Hoffnung, L.; Greenberg, D.; Dalal, I.; Livni, G.; Chapnick, G.; Stein-Zamir, C.; Ashkenazi, S.; Hecht-Sagie, L.; Grossman, Z. The Burden of COVID-19 in Children and Its Prevention by Vaccination: A Joint Statement of the Israeli Pediatric Association and the Israeli Society for Pediatric Infectious Diseases. Vaccines 2022, 10, 81. https://doi.org/10.3390/vaccines10010081

AMA Style

Stein M, Ashkenazi-Hoffnung L, Greenberg D, Dalal I, Livni G, Chapnick G, Stein-Zamir C, Ashkenazi S, Hecht-Sagie L, Grossman Z. The Burden of COVID-19 in Children and Its Prevention by Vaccination: A Joint Statement of the Israeli Pediatric Association and the Israeli Society for Pediatric Infectious Diseases. Vaccines. 2022; 10(1):81. https://doi.org/10.3390/vaccines10010081

Chicago/Turabian Style

Stein, Michal, Liat Ashkenazi-Hoffnung, David Greenberg, Ilan Dalal, Gilat Livni, Gil Chapnick, Chen Stein-Zamir, Shai Ashkenazi, Lior Hecht-Sagie, and Zachi Grossman. 2022. "The Burden of COVID-19 in Children and Its Prevention by Vaccination: A Joint Statement of the Israeli Pediatric Association and the Israeli Society for Pediatric Infectious Diseases" Vaccines 10, no. 1: 81. https://doi.org/10.3390/vaccines10010081

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop